A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
Merck Sharp & Dohme LLC
Study ID
NCT06818643
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Advanced Solid Tumors
  • Malignant Neoplasm

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • MK-3120 — BIOLOGICAL
    IV infusion

Study Details

Researchers are looking for new ways to treat people with certain advanced solid tumors. Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery. Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids. The main goal of this study is to learn about the safety of MK-3120 and if people tolerate it.

Key Dates

Start date
Mar 25, 2025
Status verified
May 2026
Primary completion
Oct 25, 2028
Completion
Mar 25, 2031

Study Design

Enrollment
270 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Arm 1 Dose level 1
    Participants receive MK-3120 at dose level 1 as per the schedule specified in the arm.
  • Experimental: Arm 2 Dose level 2
    Participants receive MK-3120 at dose level 2 as per the schedule specified in the arm.

Primary Outcome Measure

Number of Participants Who Experience an Adverse Event (AE) [ Time Frame: Up to approximately 43 months ]

Central Contacts

Locations (7)

FacilityCityStateZIPSite coordinators
The University of Alabama at Birmingham ( Site 1005)BirminghamAlabama35249
Study Coordinator
205-934-4199
University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 1003)MiamiFlorida33136
Study Coordinator
305-243-5302
John Theurer Cancer Center at Hackensack University Medical Center ( Site 1009)HackensackNew Jersey07601
Study Coordinator
551-996-5900
NEXT Oncology ( Site 1010)AustinTexas78758
Study Coordinator
737-610-5202
NEXT Oncology ( Site 1011)HoustonTexas77054
Study Coordinator
832-384-7912
NEXT Oncology ( Site 1012)IrvingTexas75039
Study Coordinator
972-893-8800
Virginia Commonwealth University ( Site 1008)RichmondVirginia23219
Study Coordinator
804-828-7999

Find similar trials in Birmingham, AL

By research site
The University of Alabama at Birmingham· Birmingham, ALUniversity of Miami Hospital and Clinics, Sylvester Cancer Center· Miami, FLJohn Theurer Cancer Center at Hackensack University Medical Center· Hackensack, NJNEXT Oncology· Austin, TXNEXT Oncology· Houston, TXNEXT Oncology· Irving, TX

Related Studies